Ron Feldman
Overview
Ron Feldman, MD PhD is an associate professor of Dermatology at the Emory University School of Medicine with a joint appointment at the Veterans Administration (VA) in Atlanta.
Dr. Feldman earned his Doctor of Medicine and Philosophy from the Medical University of South Carolina. He then completed a Dermatology Research Residency at Cleveland Clinic followed by a clinical fellowship in Autoimmune Blistering Diseases in Boston.
Dr. Feldman has extensive experience in treating patients with rare Autoimmune Blistering Diseases and receives referrals from all over Georgia and the Southeast United States. He runs a translational research program for 1) improving understanding and therapeutics for patients, 2) analyzing disease and treatment specific effects on patient quality of life, and 3) exploring immunological mechanisms involved in alteration of cellular adhesion. His research is supported by grants from the National Institutes of Health, Corporate collaborations and Private philanthropy.
Dr. Feldman is a Fellow of the American Academy of Dermatology and holds memberships in the Medical Dermatology Society, Society for Investigative Dermatology and the Atlanta Association for Dermatology and Dermatologic Surgery.
Academic Appointment
- Associate Professor, Dermatology, Emory University School of Medicine
Education
Degrees
- BS from College of Charleston
- PhD from Medical University of South Carolina
- MD from Medical University of South Carolina
- Dermatology Residency from Cleveland Clinic
Research
Publications
-
The Impact of Air Pollution on Disease Activity in Bullous Pemphigoid and Pemphigus.
JID Innov Volume: 5 Page(s): 100334
05/01/2025 Authors: Feldman R; Cole EF -
Clinical Observational Study Utilizing Teledermatology in Bullous Pemphigoid.
J Invest Dermatol
03/18/2025 Authors: Osuoji O; Adkins T; Barron J; Chen Y; Yue S; Liu Y; Stokes J; Bradley B; Chen S; Yeung H -
Exploring Pruritus in Bullous Pemphigoid: Analysis of QOL Metrics and Potential Biological Mechanisms.
JID Innov Volume: 5 Page(s): 100329
03/01/2025 Authors: Osuoji OC; DeGrazia T; Rolader R; Cole EF; Lawson K; Hilley H; Xing Y; Han L; Chisolm S; Claussen H -
Pemphigus-Associated Desmoglein-Specific IgG1 and IgG4 Have a Dominant Agalactosylated Glycan Modification.
J Invest Dermatol Volume: 144 Page(s): 2584 - 2587.e6
11/01/2024 Authors: Oloumi A; Le ST; Liu Y; Herbert S; Ji-Xu A; Merleev AA; Kruglinskaya O; Artounian K; Park D; Marusina AI -
The safety of topical vs. oral steroids in bullous pemphigoid: considerations for retrospective analyses.
Br J Dermatol Volume: 191 Page(s): 479 - 480
09/18/2024 Authors: Amber KT; Feldman RJ -
HIV-related exclusion criteria in atopic dermatitis and prurigo nodularis clinical trials.
J Am Acad Dermatol Volume: 91 Page(s): 352 - 354
08/01/2024 Authors: Leibowitz R; Fischer A; Collins LF; Feldman RJ; Yeung H -
Disease severity and hospitalization risk factors in a cohort of Hispanic/Latino pemphigus patients: A descriptive retrospective chart review.
J Am Acad Dermatol Volume: 90 Page(s): 1306 - 1308
06/01/2024 Authors: Leibowitz R; Seely M; Holms LR; Mustin D; Guo R; Feldman RJ; Marano AL -
Comparing Clinical Outcomes of Steroid-Sparing Therapy With Rituximab Versus Rituximab Alone in Pemphigus.
J Drugs Dermatol Volume: 23 Page(s): e97 - e99
03/01/2024 Authors: Mustin DE; Cole EF; Leibowitz R; Feldman RJ -
Autoimmune encephalitis associated with autoimmune blistering diseases: A case series and retrospective review.
JAAD Case Rep Volume: 37 Page(s): 92 - 97
07/01/2023 Authors: Tadros AR; Atteh G; Vargas DL; Cole EF; Feldman RJ -
New-Onset Pemphigoid Gestationis Following COVID-19 Vaccination.
Cutis Volume: 111 Page(s): E2 - E4
05/01/2023 Authors: Mustin DE; Huffaker TB; Feldman RJ